In comparison with the Scramble group, TP63-knockdown strongly augmented tumor cell killing by CD8+ T cells in both MOC22 and AKR cell lines, at different effector: target ratios (Fig. 5B, C and Supplementary Fig. 6A, B). This evidence concerns the gene CD8A and neoplasm.